Loading...
•
Dec 31, 2024
ClearPoint Neuro Q4 2024 Earnings Report
ClearPoint Neuro reported a strong fourth quarter and full-year 2024 financial performance, achieving record revenue and significantly reducing operational cash burn.
Key Takeaways
ClearPoint Neuro, Inc. announced record revenue of $7.8 million for the fourth quarter of 2024, a 14% increase year-over-year, and $31.4 million for the full year, up 31% from 2023. The company also reduced its total 2024 operational cash burn by 35% to $9.0 million.
Fourth quarter 2024 revenue increased by 14% year-over-year to $7.8 million.
Full year 2024 revenue reached a record $31.4 million, marking the tenth consecutive year of growth.
Operational cash burn for 2024 was reduced by 35% compared to 2023, totaling $9.0 million.
The company activated 25 new global centers in 2024, approximately three times its historic activation rate.
ClearPoint Neuro
ClearPoint Neuro
ClearPoint Neuro Revenue by Segment
Revenue by Segment
Biologics and Drug Delivery Revenue
CapyFin.comNeurosurgery Navigation & Therapy Revenue
CapyFin.comCapital Equipment & Software Revenue
CapyFin.com Forward Guidance
ClearPoint Neuro estimates its 2025 revenue to be between $36.0 million and $41.0 million, representing a growth of 15% to 31%. The company plans to extend its lead in drug delivery, expand its global footprint, and accelerate the launch of new products.
Positive Outlook
- Estimated revenue growth of 15% to 31% in 2025.
- Plans to extend leadership as a premier drug delivery partner for neuro disorders.
- Intends to build a leading solution in the drug delivery ecosystem, including hardware, software, and services.
- Aims to expand global footprint and regulatory clearances to increase patient capacity.
- Will accelerate the launch of new fast, simple, and predictable products for MRI Suite and Operating Room.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- The company did not highlight any specific challenges or risks for the upcoming year in the guidance section.
- No mention of potential market headwinds or increased competition.
- No specific financial targets for expenses or profitability were provided for 2025.
- The guidance does not include any potential impacts from unforeseen global economic or health events.
Revenue & Expenses
Visualization of income flow from segment revenue to net income